Publication | Open Access
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation
18
Citations
34
References
2022
Year
Despite the emergence of K65N/R +/- M184V/I after virologic failures, BIC/FTC/TAF could be an option for simplification after viral suppression.
| Year | Citations | |
|---|---|---|
Page 1
Page 1